FDA chief to depart after Trump signed off on ousting him

FDA chief to depart after Trump signed off on ousting him

FDA chief to depart after Trump – FDA Commissioner Marty Makary has announced his exit from the Trump administration, according to three sources close to the situation. The decision followed President Donald Trump’s approval of a plan to remove Makary last week, marking a significant shift in the leadership of the U.S. Health and Human Services Department. Makary’s departure comes amid growing tensions within the agency and the White House, with his resistance to approving flavored e-cigarettes becoming a central point of contention.

Internal and External Pressure

Makary faced consistent challenges from within the administration, including pushback over his stance on flavored e-cigarettes. This issue had drawn direct attention from Trump, who confronted the commissioner during a recent meeting. Additionally, external groups such as pharmaceutical companies and anti-abortion organizations had criticized Makary’s policies, amplifying the pressure on him to align with broader political goals. The commissioner’s leadership also experienced frequent changes in senior roles, contributing to a climate of uncertainty within the FDA.

Trump is set to appoint Kyle Diamantas, a deputy commissioner overseeing the agency’s food program, as acting FDA chief. The move was confirmed through a Truth Social post, where the president explicitly stated Makary’s resignation and Diamantas’ interim role. However, Makary’s exit leaves the administration with another key leadership vacancy, as the permanent replacement will require Senate confirmation. This follows the existing absence of a permanent CDC director and surgeon general, both of whom are traditionally considered high-profile figures in the health sector.

Testimony and Timing

Makary’s resignation occurs just one day before he was scheduled to appear before the Senate Appropriations Committee to discuss the FDA’s proposed budget. The timing of his departure has sparked questions about the internal dynamics of the Trump team, with some sources suggesting the decision was made hastily to address mounting criticism. Politico was the first to report his resignation, highlighting the administration’s shift in priorities and the rapid pace of leadership changes.

The push to replace Makary intensified in recent days, driven by a group of White House and HHS officials who grew frustrated with the FDA’s perceived instability. These officials argued that the agency had become a source of confusion, with conflicting policies and a lack of clear direction. Despite this, some Trump aides had previously resisted the idea of ousting another senior health official, fearing it might alienate the “Make America Healthy Again” movement and increase the workload on the Senate ahead of the midterms.

Policy Conflicts and Reversals

Throughout his tenure, Makary faced controversy for his approach to drug approvals and other regulatory decisions. His commitment to expediting FDA decisions on pharmaceuticals, medical devices, and vaccines was overshadowed by disputes with industry stakeholders and internal conflicts. The recent reversal on flavored e-cigarettes, which followed his initial opposition, underscores the extent to which Trump’s administration has prioritized political alignment over scientific consensus.

In a notable episode, Susan B. Anthony Pro-Life America’s President Marjorie Dannenfelser met with White House officials to advocate for the FDA’s regulatory changes. Her influence played a role in the administration’s broader strategy to reshape the agency’s policies, particularly those affecting tobacco and reproductive health. Meanwhile, pharmaceutical companies criticized Makary’s management style, citing delays and perceived biases in the drug approval process. These disputes contributed to the growing sentiment that his leadership was no longer aligned with the administration’s objectives.

Leadership Transition and Future Plans

Health and Human Services Secretary Robert F. Kennedy Jr. expressed support for Makary in a recent X post, stating, “The search for a new Commissioner is already underway, and we will move forward with urgency.” This remark highlights the complexity of the transition, as the administration balances internal factions and external pressures. Diamantas, who has long been associated with the FDA’s food division, is expected to take on the role of acting chief, though his leadership style may differ from Makary’s.

Makary’s resignation also signals a broader effort to restructure the FDA’s senior staff. White House and HHS officials are reportedly considering changes to the agency’s leadership, aiming to strengthen ties with key constituencies such as the anti-abortion movement and the drug industry. This restructuring is seen as a way to consolidate power and ensure smoother implementation of Trump’s health policy agenda before the November elections.

While Makary sought to reassure Trump of his loyalty, some associates noted that his efforts were not enough to prevent the decision. He had previously told close allies that the president still valued his contributions, but that confidence was shaken when reports emerged of Trump’s approval to remove him. The rapid pace of the announcement surprised many within the administration, who had anticipated a more drawn-out process.

The FDA chief’s departure reflects the administration’s focus on aligning regulatory decisions with political goals. Makary’s resistance to flavored e-cigarettes, which had sparked a direct confrontation with Trump, became the catalyst for his removal. His decision to reverse course on the issue last week demonstrates the influence of the White House in shaping the agency’s policies, even when they conflict with scientific or public health considerations.

As the Trump administration moves to fill the FDA vacancy, the focus remains on securing Senate approval for the permanent replacement. This process will require careful negotiation, as the new commissioner must navigate the complex landscape of industry interests and public health priorities. Meanwhile, the HHS department continues to face challenges in maintaining stable leadership amid ongoing restructuring and political maneuvering.